Profile data is unavailable for this security.
About the company
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
- Revenue in USD (TTM)20.87m
- Net income in USD-23.82m
- Incorporated2013
- Employees46.00
- LocationPieris Pharmaceuticals Inc225 Franklin Street, 26Th FloorBOSTON 02110United StatesUSA
- Phone+1 (857) 246-8998
- Fax+49 (8161) 141-1444
- Websitehttps://www.pieris.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 18.98m | 29.00 | -- | -- | -- | -- | -0.2242 | -0.2242 | 0.00 | -0.0443 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
NanoViricides Inc | 0.00 | -9.51m | 19.61m | 7.00 | -- | 1.84 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
Nymox Pharmaceutical Corp | 0.00 | -8.84m | 19.64m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
Minerva Neurosciences Inc | 0.00 | -33.65m | 19.93m | 9.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -6.36 | 0.00 | -- | -- | 0.00 | -59.32 | -49.89 | -62.70 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
MEI Pharma Inc | 66.75m | 26.16m | 20.26m | 46.00 | 0.7744 | 0.3969 | 0.764 | 0.3034 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Vincerx Pharma Inc | 0.00 | -28.90m | 20.41m | 42.00 | -- | 1.32 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 21.34m | 46.00 | -- | 1.14 | -- | 1.02 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Palatin Technologies, Inc. | 5.90m | -32.20m | 21.95m | 34.00 | -- | 13.90 | -- | 3.72 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
Geovax Labs Inc | 300.68k | -26.92m | 22.56m | 17.00 | -- | -- | -- | 75.03 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Hcw Biologics Inc | 3.92m | -38.37m | 22.69m | 45.00 | -- | -- | -- | 5.78 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.78m | -40.32m | 23.63m | 57.00 | -- | 0.5123 | -- | 8.50 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Biora Therapeutics Inc | 860.00k | -86.81m | 23.74m | 58.00 | -- | -- | -- | 27.60 | -5.57 | -5.56 | 0.024 | -2.49 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
RenovoRx Inc | 0.00 | -8.11m | 23.75m | 8.00 | -- | 2.56 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Bolt Biotherapeutics Inc | 11.17m | -66.17m | 23.79m | 100.00 | -- | 0.2771 | -- | 2.13 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
Unity Biotechnology Inc | 0.00 | -27.86m | 23.92m | 19.00 | -- | 1.21 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 30 Jun 2024 | 257.63k | 19.51% |
Adar1 Capital Management LLCas of 12 Aug 2024 | 144.64k | 10.96% |
Dellora Investments LPas of 24 Jul 2024 | 108.97k | 8.25% |
Lynx1 Capital Management LPas of 30 Jun 2024 | 43.50k | 3.30% |
Hudson Valley Investment Advisors, Inc.as of 30 Jun 2024 | 14.00k | 1.06% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 12.94k | 0.98% |
Renaissance Technologies LLCas of 30 Jun 2024 | 11.47k | 0.87% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 11.07k | 0.84% |
Acadian Asset Management LLCas of 30 Jun 2024 | 10.83k | 0.82% |
Geode Capital Management LLCas of 30 Jun 2024 | 10.62k | 0.81% |